Atavistik Bio to Highlight Momentum Across Hematology Pipeline with Harmony-HHT Clinical Trial Update and New Preclinical Data from HHT and JAK2 V617F Programs at ASH 2026

・ アタビスティック・バイオ 臨床

Atavistik Bio will present three posters at the 68th ASH Annual Meeting in New Orleans, December 12-15. They cover an update on the Harmony-HHT study of ATV-1601 and preclinical data on AKT1 inhibition and a JAK2 V617F mutant-selective inhibitor.

Atavistik Bioで全文を読む ↗

アタビスティック・バイオ の他のリリース